Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency

Atherosclerosis Supplements

Volumn 11, Issue 1, 2010, Pages 55-60

  Gaudet, Daniel ^a   de Wal, Janneke ^b   Tremblay, Karine ^a   Déry, Stéphane ^a   van Deventer, Sander ^b   Freidig, Andreas ^b   Brisson, Diane ^a   Méthot, Julie ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b Amsterdam Molecular Therapeutics   (Netherlands)

Author keywords

Chylomicronaemia; Gene therapy; Lipoprotein lipase; Pancreatitis

Indexed keywords

ALIPOGENE TIPARVOVEC; AMT 010; AMT 011; ANTILIPEMIC AGENT; CYCLOSPORIN; GENE THERAPY AGENT; GLYBERA; HIGH DENSITY LIPOPROTEIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARVOVIRUS VECTOR; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ACUTE PANCREATITIS; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; CHYLOMICRONEMIA; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; GENE THERAPY; HUMAN; HYPERLIPOPROTEINEMIA TYPE 1; HYPERTRIGLYCERIDEMIA; LOW DRUG DOSE; LOW FAT DIET; METABOLIC DISORDER; NONHUMAN; PANCREATITIS; PRIORITY JOURNAL;

ANIMALS; DEPENDOVIRUS; EVIDENCE-BASED MEDICINE; GENE THERAPY; GENETIC VECTORS; HUMANS; HYPERLIPOPROTEINEMIA TYPE I; INJECTIONS, INTRAMUSCULAR; LIPOPROTEIN LIPASE; PANCREATITIS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 77952571307     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2010.03.004     Document Type: Article

References (33)

1. Brunzell J.D., and Deeb S.S. Familial lipoprotein lipase deficiency, Apo C-II deficiency and hepatic lipase deficiency. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The metabolic basis of inherited disease. 8th ed. (2000), McGraw-Hill, New York 2789-2816
2. Goldberg I.J., and Merkel M. Lipoprotein lipase: physiology, biochemistry, and molecular biology. Front Biosci 6 (2001) D388-405
3. Gagne C., Brun L.D., Julien P., et al. Primary lipoprotein-lipase-activity deficiency: clinical investigation of a French Canadian population. CMAJ 140 (1989) 405-411
4. Franssen R., Young S.G., Peelman F., et al. Chylomicronemia with low postheparin lipoprotein lipase levels in the setting of GPIHBP1 defects. Circ Cardiovasc Genet (2010)
5. Pruneta-Deloche V., Marcais C., Perrot L., et al. Combination of circulating antilipoprotein lipase (Anti-LPL) antibody and heterozygous S172 fsX179 mutation of LPL gene leading to chronic hyperchylomicronemia. J Clin Endocrinol Metab 90 (2005) 3995-3998
6. Black D.M., and Sprecher D.L. Dietary treatment and growth of hyperchylomicronemic children severely restricted in dietary fat. Am J Dis Child 147 (1993) 60-62
7. Santamarina-Fojo S. The familial chylomicronemia syndrome. Endocrinol Metab Clin N Am 27 (1998) 551-567
8. Fortson M.R., Freedman S.N., and Webster III P.D. Clinical assessment of hyperlipidemic pancreatitis. Am J Gastroenterol 90 (1995) 2134-2139
9. Etemad B., and Whitcomb D.C. Chronic pancreatitis: diagnosis, classification, and new genetic developments. Gastroenterology 120 (2001) 682-707
10. Benlian P., De Gennes J.L., Foubert L., et al. Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. N Engl J Med 335 (1996) 848-854
11. Frossard J.L., Steer M.L., and Pastor C.M. Acute pancreatitis. Lancet 371 (2008) 143-152
12. Chen J.M., and Ferec C. Chronic pancreatitis: genetics and pathogenesis. Annu Rev Genomics Hum Genet 10 (2009) 63-87
13. Schneider A., Barmada M.M., Slivka A., et al. Clinical characterization of patients with idiopathic chronic pancreatitis and SPINK1 mutations. Scand J Gastroenterol 39 (2004) 903-904
14. Cohn J.A., Friedman K.J., Noone P.G., et al. Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. N Engl J Med 339 (1998) 653-658
15. Whitcomb D.C. Genetic aspects of pancreatitis. Annu Rev Med 61 (2010) 413-424
16. Criddle D.N., McLaughlin E., Murphy J.A., et al. The pancreas misled: signals to pancreatitis. Pancreatology 7 (2007) 436-446
17. Ferns G., Keti V., and Griffin B. Investigation and management of hypertriglyceridaemia. J Clin Pathol 61 (2008) 1174-1183
18. Chait A., and Brunzell J.D. Chylomicronemia syndrome. Adv Intern Med 37 (1992) 249-273
19. Paradis G. Effect of a nutritional supplement rich containing medium-chain triglyceride (MCT) and the adjunction of fibrates on lipid-lipoprotein profile in subjects with homozygous LPL deficiency. Master of Sciences Thesis, Université Laval, Québec; 2001.
20. Rip J., van Dijk K.W., Sierts J.A., et al. AAV1-LPL(S447X) gene therapy reduces hypertriglyceridemia in apoE2 knock in mice. Biochim Biophys Acta 1761 (2006) 1163-1168
21. Wittrup H.H., Tybjaerg-Hansen A., and Nordestgaard B.G. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation 99 (1999) 2901-2907
22. Ak K., Isbir S., Tekeli A., et al. Presence of lipoprotein lipase S447X stop codon affects the magnitude of interleukin 8 release after cardiac surgery with cardiopulmonary bypass. J Thorac Cardiovasc Surg 134 (2007) 477-483
23. Stroes E.S., Nierman M.C., Meulenberg J.J., et al. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol 28 (2008) 2303-2304
24. Rip J., Nierman M.C., Sierts J.A., et al. Gene therapy for lipoprotein lipase deficiency: working toward clinical application. Hum Gene Ther 16 (2005) 1276-1286
25. Mingozzi F., Meulenberg J.J., Hui D.J., et al. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood 114 (2009) 2077-2086
26. Frimat L., Cassuto-Viguier E., Charpentier B., et al. Impact of cyclosporine reduction with MMF: a randomized trial in chronic allograft dysfunction. The 'reference' study. Am J Transplant 6 (2006) 2725-2734
27. Vogt B., Antoniadis A., Klinger M., and Vitko S. Efficacy and safety of enteric-coated mycophenolate sodium (myfortic) in de novo renal transplant recipients: results of a 12-month multicenter, open-label, prospective study. Transplant Proc 38 (2006) 1301-1306.26
28. Sadek S., Medina J., Arias M., et al. Short-term combination of mycophenolate mofetil with cyclosporine as a therapeutic option for renal transplant recipients: a prospective, multicenter, randomized study. Transplantation 74 (2002) 511-517
29. Ahsan N., Johnson C., Gonwa T., et al. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years. Transplantation 72 (2001) 245-250
30. Lachin J.M. Biostatistical methods: the assessment of relative risks. 1st ed. (2000), J Wiley, New York 544 pp.
31. Kimmelman J. Recent developments in gene transfer: risk and ethics. BMJ 330 (2005) 79-82
32. Deakin C.T., Alexander I.E., and Kerridge I. Accepting risk in clinical research: is the gene therapy field becoming too risk-averse?. Mol Ther 17 (2009) 1842-1848
33. Kaplan S., and Garrick B.J. On the quantitative definition of risk. Risk Anal 1 (1981) 11-27